Safety of ACE-I and ARB medications in COVID-19: A retrospective cohort study of inpatients and outpatients in California.
Safety of ACE-I and ARB medications in COVID-19: A retrospective cohort study of inpatients and outpatients in California.
复制标题
DOI：
10.1017/cts.2020.489
复制
发表时间：
2021
影响因子：
2.6
通讯作者：
Blish CA
中科院分区：
文献类型：
--
作者：
Rubin SJS;Falkson SR;Degner NR;Blish CA
There is significant interest in the use of angiotensin converting enzyme inhibitors (ACE-I) and angiotensin II receptor blockers (ARB) in coronavirus disease 2019 (COVID-19) and concern over potential adverse effects since these medications upregulate the severe acute respiratory syndrome coronavirus 2 host cell entry receptor ACE2. Recent studies on ACE-I and ARB in COVID-19 were limited by excluding outpatients, excluding patients by age, analyzing ACE-I and ARB together, imputing missing data, and/or diagnosing COVID-19 by chest computed tomography without definitive reverse transcription polymerase chain reaction (RT-PCR), all of which are addressed here. We performed a retrospective cohort study of 1023 COVID-19 patients diagnosed by RT-PCR at Stanford Hospital through April 8, 2020 with a minimum follow-up time of 14 days to investigate the association between ACE-I or ARB use with outcomes. Use of ACE-I or ARB medications was not associated with increased risk of hospitalization, intensive care unit admission, or death. Compared to patients with charted past medical history, there was a lower risk of hospitalization for patients on ACE-I (odds ratio (OR) 0.43; 95% confidence interval (CI) 0.19–0.97; P = 0.0426) and ARB (OR 0.39; 95% CI 0.17–0.90; P = 0.0270). Compared to patients with hypertension not on ACE-I or ARB, patients on ARB medications had a lower risk of hospitalization (OR 0.09; 95% CI 0.01–0.88; P = 0.0381). These findings suggest that the use of ACE-I and ARB is not associated with adverse outcomes and may be associated with improved outcomes in COVID-19, which is immediately relevant to care of the many patients on these medications.
登录
查看更多内容
影响因子：
11.8
作者：
Hanff, Thomas C.;Harhay, Michael O.;Mohareb, Annie M.
通讯作者：
Mohareb, Annie M.
影响因子：
158.5
作者：
Vaduganathan, Muthiah;Vardeny, Orly;Solomon, Scott D.
通讯作者：
Solomon, Scott D.
DOI：
10.1080/08998280.2018.1499293
发表时间：
2018-10-01
期刊：
Proceedings (Baylor University. Medical Center)
影响因子：
--
作者：
Henry, Christopher;Zaizafoun, Manaf;White, Heath D
通讯作者：
White, Heath D
影响因子：
82.9
作者：
Kuba K;Imai Y;Rao S;Gao H;Guo F;Guan B;Huan Y;Yang P;Zhang Y;Deng W;Bao L;Zhang B;Liu G;Wang Z;Chappell M;Liu Y;Zheng D;Leibbrandt A;Wada T;Slutsky AS;Liu D;Qin C;Jiang C;Penninger JM
通讯作者：
Penninger JM
影响因子：
64.8
作者：
Imai Y;Kuba K;Rao S;Huan Y;Guo F;Guan B;Yang P;Sarao R;Wada T;Leong-Poi H;Crackower MA;Fukamizu A;Hui CC;Hein L;Uhlig S;Slutsky AS;Jiang C;Penninger JM
通讯作者：
Penninger JM